Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Better Able To De-Risk First-In-Class Compounds, R&D Head Says

Executive Summary

Pfizer has become more effective at controlling the development risk of investigational compounds with novel mechanisms of action, Global Research & Development President John LaMattina asserted Nov. 30
Advertisement

Related Content

Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer Looks To Combination Regimens To Maximize Oncology Pipeline Value
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Advertisement
UsernamePublicRestriction

Register

PS047831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel